Development and Standardization of a Furosemide Stress Test to Predict the Severity of Acute Kidney Injury

In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. We investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development...

Full description

Saved in:
Bibliographic Details
Published inCritical care (London, England) Vol. 17; no. 5; p. R207
Main Authors Chawla, Lakhmir S, Davison, Danielle L, Brasha-Mitchell, Ermira, Koyner, Jay L, Arthur, John M, Shaw, Andrew D, Tumlin, James A, Trevino, Sharon A, Kimmel, Paul L, Seneff, Michael G
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 20.09.2013
BioMed Central
Subjects
Online AccessGet full text

Cover

Loading…
Abstract In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. We investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development of AKIN Stage-III in 2 cohorts of critically ill subjects with early AKI. Cohort 1 was a retrospective cohort who received a FST in the setting of AKI in critically ill patients as part of Southern AKI Network. Cohort 2 was a prospective multicenter group of critically ill patients who received their FST in the setting of early AKI. We studied 77 subjects; 23 from cohort 1 and 54 from cohort 2; 25 (32.4%) met the primary endpoint of progression to AKIN-III. Subjects with progressive AKI had significantly lower urine output following FST in each of the first 6 hours (p<0.001). The area under the receiver operator characteristic curves for the total urine output over the first 2 hours following FST to predict progression to AKIN-III was 0.87 (p = 0.001). The ideal-cutoff for predicting AKI progression during the first 2 hours following FST was a urine volume of less than 200mls(100ml/hr) with a sensitivity of 87.1% and specificity 84.1%. The FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI. Future studies to validate these findings are warranted.
AbstractList In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. We investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development of AKIN Stage-III in 2 cohorts of critically ill subjects with early AKI. Cohort 1 was a retrospective cohort who received a FST in the setting of AKI in critically ill patients as part of Southern AKI Network. Cohort 2 was a prospective multicenter group of critically ill patients who received their FST in the setting of early AKI. We studied 77 subjects; 23 from cohort 1 and 54 from cohort 2; 25 (32.4%) met the primary endpoint of progression to AKIN-III. Subjects with progressive AKI had significantly lower urine output following FST in each of the first 6 hours (p<0.001). The area under the receiver operator characteristic curves for the total urine output over the first 2 hours following FST to predict progression to AKIN-III was 0.87 (p = 0.001). The ideal-cutoff for predicting AKI progression during the first 2 hours following FST was a urine volume of less than 200mls(100ml/hr) with a sensitivity of 87.1% and specificity 84.1%. The FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI. Future studies to validate these findings are warranted.
INTRODUCTION: In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. METHODS: We investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development of AKIN Stage-III in 2 cohorts of critically ill subjects with early AKI. Cohort 1 was a retrospective cohort who received a FST in the setting of AKI in critically ill patients as part of Southern AKI Network. Cohort 2 was a prospective multicenter group of critically ill patients who received their FST in the setting of early AKI. RESULTS: We studied 77 subjects; 23 from cohort 1 and 54 from cohort 2; 25 (32.4%) met the primary endpoint of progression to AKIN-III. Subjects with progressive AKI had significantly lower urine output following FST in each of the first 6 hours (p<0.001). The area under the receiver operator characteristic curves for the total urine output over the first 2 hours following FST to predict progression to AKIN-III was 0.87 (p = 0.001). The ideal-cutoff for predicting AKI progression during the first 2 hours following FST was a urine volume of less than 200mls(100ml/hr) with a sensitivity of 87.1% and specificity 84.1%. CONCLUSIONS: The FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI. Future studies to validate these findings are warranted.
In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages.INTRODUCTIONIn the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages.We investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development of AKIN Stage-III in 2 cohorts of critically ill subjects with early AKI. Cohort 1 was a retrospective cohort who received a FST in the setting of AKI in critically ill patients as part of Southern AKI Network. Cohort 2 was a prospective multicenter group of critically ill patients who received their FST in the setting of early AKI.METHODSWe investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development of AKIN Stage-III in 2 cohorts of critically ill subjects with early AKI. Cohort 1 was a retrospective cohort who received a FST in the setting of AKI in critically ill patients as part of Southern AKI Network. Cohort 2 was a prospective multicenter group of critically ill patients who received their FST in the setting of early AKI.We studied 77 subjects; 23 from cohort 1 and 54 from cohort 2; 25 (32.4%) met the primary endpoint of progression to AKIN-III. Subjects with progressive AKI had significantly lower urine output following FST in each of the first 6 hours (p<0.001). The area under the receiver operator characteristic curves for the total urine output over the first 2 hours following FST to predict progression to AKIN-III was 0.87 (p = 0.001). The ideal-cutoff for predicting AKI progression during the first 2 hours following FST was a urine volume of less than 200mls(100ml/hr) with a sensitivity of 87.1% and specificity 84.1%.RESULTSWe studied 77 subjects; 23 from cohort 1 and 54 from cohort 2; 25 (32.4%) met the primary endpoint of progression to AKIN-III. Subjects with progressive AKI had significantly lower urine output following FST in each of the first 6 hours (p<0.001). The area under the receiver operator characteristic curves for the total urine output over the first 2 hours following FST to predict progression to AKIN-III was 0.87 (p = 0.001). The ideal-cutoff for predicting AKI progression during the first 2 hours following FST was a urine volume of less than 200mls(100ml/hr) with a sensitivity of 87.1% and specificity 84.1%.The FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI. Future studies to validate these findings are warranted.CONCLUSIONSThe FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI. Future studies to validate these findings are warranted.
In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. We investigated the ability of a furosemide stress test (FST) (one-time dose of 1.0 or 1.5 mg/kg depending on prior furosemide-exposure) to predict the development of AKIN Stage-III in 2 cohorts of critically ill subjects with early AKI. Cohort 1 was a retrospective cohort who received a FST in the setting of AKI in critically ill patients as part of Southern AKI Network. Cohort 2 was a prospective multicenter group of critically ill patients who received their FST in the setting of early AKI. We studied 77 subjects; 23 from cohort 1 and 54 from cohort 2; 25 (32.4%) met the primary endpoint of progression to AKIN-III. Subjects with progressive AKI had significantly lower urine output following FST in each of the first 6 hours (p<0.001). The area under the receiver operator characteristic curves for the total urine output over the first 2 hours following FST to predict progression to AKIN-III was 0.87 (p = 0.001). The ideal-cutoff for predicting AKI progression during the first 2 hours following FST was a urine volume of less than 200mls(100ml/hr) with a sensitivity of 87.1% and specificity 84.1%. The FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI. Future studies to validate these findings are warranted.
ArticleNumber R207
Audience Academic
Author Koyner, Jay L
Tumlin, James A
Brasha-Mitchell, Ermira
Shaw, Andrew D
Trevino, Sharon A
Davison, Danielle L
Arthur, John M
Seneff, Michael G
Kimmel, Paul L
Chawla, Lakhmir S
AuthorAffiliation 1 Department of Anesthesiology and Critical Care Medicine, George Washington University Medical Center, 900 23rd street, Washington DC, 20037, USA
3 Section of Nephrology, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, Chicago, IL, 60637, USA
7 Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes, Digestive, and Kidney Diseases, NIH, 6707 Democracy Blvd, Bethesda, MD, 20817, USA
4 829 CSB Division of Nephrology, Department of Medicine, Medical University of South Carolina, 96 Jonathan Lucas, Charleston, SC, 250623, USA
5 Department of Anesthesiology, Duke University/Durham VAMC, Durham, DUMC 3094, Durham, NC, 27710, USA
2 Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue, Washington DC, 20037, USA
6 Renal Division, University of Tennessee College of Medicine at Chattanooga, 251 North Lyerly Street, Chattanooga, TN, 37404, USA
AuthorAffiliation_xml – name: 3 Section of Nephrology, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, Chicago, IL, 60637, USA
– name: 2 Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue, Washington DC, 20037, USA
– name: 5 Department of Anesthesiology, Duke University/Durham VAMC, Durham, DUMC 3094, Durham, NC, 27710, USA
– name: 7 Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes, Digestive, and Kidney Diseases, NIH, 6707 Democracy Blvd, Bethesda, MD, 20817, USA
– name: 6 Renal Division, University of Tennessee College of Medicine at Chattanooga, 251 North Lyerly Street, Chattanooga, TN, 37404, USA
– name: 4 829 CSB Division of Nephrology, Department of Medicine, Medical University of South Carolina, 96 Jonathan Lucas, Charleston, SC, 250623, USA
– name: 1 Department of Anesthesiology and Critical Care Medicine, George Washington University Medical Center, 900 23rd street, Washington DC, 20037, USA
Author_xml – sequence: 1
  givenname: Lakhmir S
  surname: Chawla
  fullname: Chawla, Lakhmir S
– sequence: 2
  givenname: Danielle L
  surname: Davison
  fullname: Davison, Danielle L
– sequence: 3
  givenname: Ermira
  surname: Brasha-Mitchell
  fullname: Brasha-Mitchell, Ermira
– sequence: 4
  givenname: Jay L
  surname: Koyner
  fullname: Koyner, Jay L
– sequence: 5
  givenname: John M
  surname: Arthur
  fullname: Arthur, John M
– sequence: 6
  givenname: Andrew D
  surname: Shaw
  fullname: Shaw, Andrew D
– sequence: 7
  givenname: James A
  surname: Tumlin
  fullname: Tumlin, James A
– sequence: 8
  givenname: Sharon A
  surname: Trevino
  fullname: Trevino, Sharon A
– sequence: 9
  givenname: Paul L
  surname: Kimmel
  fullname: Kimmel, Paul L
– sequence: 10
  givenname: Michael G
  surname: Seneff
  fullname: Seneff, Michael G
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24053972$$D View this record in MEDLINE/PubMed
BookMark eNp1kl1rFDEUhoNUbLuK_0AGvNCbqclkMpn1Qliq1WJBwXodMslJm2Um2SYzhfXXe9Zdy64fBJJDznPe5HyckqMQAxDynNEzxtrmjTGMUyYekRPGm7psBRdHe_YxOc15SSmTbcOfkOOqpoLPZXVClu_hHvq4GiCMhQ62-DbirpP1P_ToYyiiK3RxMaWYYfAW0J8g5-Ia8liMsfiawHqD5i26UCr5cb2JWZhphOKztwHWxWVYTmn9lDx2us_wbHfOyPeLD9fnn8qrLx8vzxdXZScEH0tBuRTMwtyZrgHTaqa1c6axzLXCdlzyzlndOll1TT1nc9ox6aizDGrWmablM_Juq7uaugGswcyS7tUq-UGntYraq0NP8LfqJt4rLIoUWJgZebsV6Hz8j8Chx8RB7TqAwa93r6d4N2GV1OCzgb7XAeKUFRO1kBIzpYi-3KI3ugflg4uoZja4WgheS9lWokLq7B8ULosNMTgGzuP9QcCL_fwf_v276Qi82gIGu5oTuAeEUbUZp71kyj9I48dfc4F_8P1f_E9W4c3P
CitedBy_id crossref_primary_10_2215_CJN_05450522
crossref_primary_10_1016_j_jtcvs_2019_11_137
crossref_primary_10_1186_s12967_024_05279_4
crossref_primary_10_1038_nrneph_2017_2
crossref_primary_10_1097_MCC_0000000000000746
crossref_primary_10_1093_ndt_gfz188
crossref_primary_10_1097_CCM_0000000000001823
crossref_primary_10_1177_2150135115623289
crossref_primary_10_12677_ACM_2023_1361432
crossref_primary_10_1038_s41598_023_31757_8
crossref_primary_10_1515_cclm_2021_0040
crossref_primary_10_1007_s00467_023_06161_z
crossref_primary_10_1007_s40620_017_0416_8
crossref_primary_10_1155_2015_729075
crossref_primary_10_5492_wjccm_v10_i6_310
crossref_primary_10_1111_aas_13599
crossref_primary_10_23876_j_krcp_23_284
crossref_primary_10_1186_s13054_015_0850_8
crossref_primary_10_1038_s41581_018_0054_y
crossref_primary_10_2215_CJN_14181021
crossref_primary_10_1053_j_ackd_2018_03_001
crossref_primary_10_34067_KID_0001342022
crossref_primary_10_1007_s00134_021_06595_9
crossref_primary_10_1007_s10741_021_10124_7
crossref_primary_10_1007_s11560_019_00381_x
crossref_primary_10_1053_j_ackd_2020_08_002
crossref_primary_10_1093_ckj_sfy022
crossref_primary_10_3390_diseases10020020
crossref_primary_10_17116_anaesthesiology20210516
crossref_primary_10_1007_s00134_018_5502_4
crossref_primary_10_1016_j_jcrc_2024_154901
crossref_primary_10_1007_s40620_019_00614_1
crossref_primary_10_1007_s40746_016_0047_7
crossref_primary_10_1007_s00467_023_06133_3
crossref_primary_10_1053_j_ackd_2016_03_007
crossref_primary_10_1093_burnst_tkad008
crossref_primary_10_1097_ALN_0000000000005215
crossref_primary_10_1053_j_ackd_2016_03_001
crossref_primary_10_1016_j_jcrc_2019_04_011
crossref_primary_10_3390_jcm9041104
crossref_primary_10_1038_s41598_024_83878_3
crossref_primary_10_3389_fmed_2021_697055
crossref_primary_10_5005_jp_journals_10071_23381
crossref_primary_10_1016_j_jcrc_2018_02_009
crossref_primary_10_1016_j_kint_2020_04_020
crossref_primary_10_1007_s00101_023_01338_5
crossref_primary_10_1186_s40697_016_0099_4
crossref_primary_10_1007_s40620_022_01534_3
crossref_primary_10_34067_KID_0001262022
crossref_primary_10_1007_s00467_016_3539_6
crossref_primary_10_1007_s12098_024_05401_w
crossref_primary_10_1053_j_ackd_2017_05_003
crossref_primary_10_1007_s00134_022_06909_5
crossref_primary_10_1007_s00134_017_4832_y
crossref_primary_10_1097_PCC_0000000000001822
crossref_primary_10_1038_s41598_024_54926_9
crossref_primary_10_1007_s40620_024_01949_0
crossref_primary_10_1055_a_2187_3045
crossref_primary_10_1681_ASN_2014121160
crossref_primary_10_1111_aor_14705
crossref_primary_10_1186_s12911_021_01740_2
crossref_primary_10_1016_j_semnephrol_2024_151512
crossref_primary_10_2215_CJN_11070821
crossref_primary_10_1177_0885066618824531
crossref_primary_10_1186_s13054_018_2192_9
crossref_primary_10_7759_cureus_53982
crossref_primary_10_1016_j_medin_2016_12_004
crossref_primary_10_1542_neo_23_3_e189
crossref_primary_10_1007_s00063_017_0400_z
crossref_primary_10_1053_j_jvca_2018_03_017
crossref_primary_10_1097_MNH_0000000000000292
crossref_primary_10_1016_j_ekir_2018_03_004
crossref_primary_10_1007_s40124_018_0184_5
crossref_primary_10_1053_j_jvca_2025_01_019
crossref_primary_10_1097_AIA_0000000000000224
crossref_primary_10_1016_j_jcrc_2024_154929
crossref_primary_10_1186_s13054_022_04121_x
crossref_primary_10_1177_1179560317730032
crossref_primary_10_1007_s00134_017_4792_2
crossref_primary_10_3389_fneph_2022_879766
crossref_primary_10_1016_j_jcrc_2020_07_004
crossref_primary_10_1007_s40620_018_0539_6
crossref_primary_10_1016_j_athoracsur_2017_03_015
crossref_primary_10_1186_s40001_023_01092_9
crossref_primary_10_1373_clinchem_2018_288068
crossref_primary_10_1016_j_kint_2019_05_026
crossref_primary_10_1097_PCC_0000000000002933
crossref_primary_10_1007_s00063_016_0159_7
crossref_primary_10_1155_2014_365186
crossref_primary_10_2169_naika_108_1212
crossref_primary_10_1186_s13054_018_2021_1
crossref_primary_10_1186_s13613_015_0095_3
crossref_primary_10_1007_s11255_024_04271_7
crossref_primary_10_1097_MNH_0000000000000707
crossref_primary_10_1590_2175_8239_jbn_2021_0003
crossref_primary_10_1159_000533478
crossref_primary_10_1186_s12944_015_0169_0
crossref_primary_10_1007_s00467_023_05920_2
crossref_primary_10_5858_arpa_2021_0411_OA
crossref_primary_10_1016_j_pcl_2022_08_003
crossref_primary_10_1055_a_2183_2448
crossref_primary_10_1097_CCM_0000000000005849
crossref_primary_10_1097_JTCCM_D_24_00003
crossref_primary_10_1080_0886022X_2021_1906701
crossref_primary_10_1152_physiol_00011_2023
crossref_primary_10_1007_s12098_023_04483_2
crossref_primary_10_1016_j_medine_2016_09_003
crossref_primary_10_1159_000501315
crossref_primary_10_1007_s00134_017_4841_x
crossref_primary_10_1053_j_ajkd_2015_12_033
crossref_primary_10_1097_MCC_0000000000000891
crossref_primary_10_1186_s12882_020_01721_z
crossref_primary_10_1161_CIRCHEARTFAILURE_120_008166
crossref_primary_10_1007_s00063_018_0413_2
crossref_primary_10_1371_journal_pone_0246595
crossref_primary_10_1007_s00467_021_04940_0
crossref_primary_10_1155_2016_6805169
crossref_primary_10_3390_ijms21093086
crossref_primary_10_1111_nep_14132
crossref_primary_10_1080_0886022X_2022_2151468
crossref_primary_10_1007_s00063_017_0346_1
crossref_primary_10_1590_2175_8239_jbn_2021_e010
crossref_primary_10_1080_1354750X_2017_1387934
crossref_primary_10_2215_CJN_12001017
crossref_primary_10_1007_s00467_023_06156_w
crossref_primary_10_1097_CCE_0000000000000112
crossref_primary_10_1016_j_jcrc_2017_07_030
crossref_primary_10_1007_s11560_024_00716_3
crossref_primary_10_1186_s13054_020_02912_8
crossref_primary_10_1016_j_medine_2017_03_005
crossref_primary_10_51847_a6dBTglkCE
crossref_primary_10_47373_rfcs_2021_v23_1924
crossref_primary_10_3928_19382359_20180619_02
crossref_primary_10_36290_aim_2019_074
crossref_primary_10_1016_j_bpg_2017_03_004
crossref_primary_10_1186_s13741_024_00416_5
crossref_primary_10_1213_ANE_0000000000003741
crossref_primary_10_1007_s00134_018_5159_z
crossref_primary_10_1016_j_athoracsur_2023_07_011
crossref_primary_10_3390_kidneydial2010008
crossref_primary_10_1097_MCC_0000000000001212
crossref_primary_10_1007_s12098_019_03096_y
crossref_primary_10_1016_j_ccc_2015_06_001
crossref_primary_10_1016_j_ekir_2016_04_005
crossref_primary_10_7759_cureus_65824
crossref_primary_10_3389_fvets_2021_659960
crossref_primary_10_1159_000446666
crossref_primary_10_1681_ASN_2014060535
crossref_primary_10_1111_apha_14181
crossref_primary_10_1016_j_cveq_2019_12_003
crossref_primary_10_1155_2019_6948710
crossref_primary_10_1186_s13613_018_0355_0
crossref_primary_10_1007_s00467_023_05885_2
crossref_primary_10_1016_j_jfma_2021_02_013
crossref_primary_10_1016_j_ccc_2015_06_013
crossref_primary_10_1055_s_0041_1732447
crossref_primary_10_1016_j_ccc_2015_06_012
crossref_primary_10_1007_s12630_020_01894_z
crossref_primary_10_1016_j_jtcvs_2018_12_076
crossref_primary_10_1016_j_jacc_2020_06_070
crossref_primary_10_1016_j_rmu_2017_10_004
crossref_primary_10_1016_j_trsl_2020_11_011
crossref_primary_10_4103_ajpn_ajpn_6_22
crossref_primary_10_1590_1806_9282_66_s1_68
crossref_primary_10_1016_j_siny_2016_12_001
crossref_primary_10_1016_j_plabm_2022_e00272
crossref_primary_10_1097_CCM_0000000000003738
crossref_primary_10_1186_cc13871
crossref_primary_10_1007_s00134_023_07171_z
crossref_primary_10_1007_s40140_019_00325_0
crossref_primary_10_1038_s41581_021_00410_w
crossref_primary_10_1097_CCM_0000000000003862
crossref_primary_10_1016_j_medin_2016_05_009
crossref_primary_10_1097_PCC_0000000000000461
crossref_primary_10_1080_0886022X_2023_2298900
crossref_primary_10_5005_jp_journals_10071_24865
crossref_primary_10_5005_jp_journals_10071_24862
crossref_primary_10_1016_j_mayocp_2019_01_040
crossref_primary_10_1016_j_ccc_2020_11_005
crossref_primary_10_1159_000449235
crossref_primary_10_1007_s40620_022_01335_8
crossref_primary_10_1371_journal_pone_0196088
crossref_primary_10_23736_S0375_9393_21_14942_9
crossref_primary_10_1038_s41390_021_01452_3
crossref_primary_10_1159_000447979
crossref_primary_10_1093_ckj_sfx003
crossref_primary_10_1371_journal_pone_0169305
crossref_primary_10_1016_j_suc_2017_07_004
crossref_primary_10_1097_ALN_0000000000004746
crossref_primary_10_1159_000529068
crossref_primary_10_1681_ASN_2014070724
crossref_primary_10_1164_rccm_201604_0799OC
crossref_primary_10_5005_jp_journals_10071_23911
crossref_primary_10_1038_s41581_024_00918_x
crossref_primary_10_1007_s11897_019_00425_2
crossref_primary_10_1186_s13613_024_01387_y
crossref_primary_10_1186_s13613_019_0509_8
crossref_primary_10_1093_bja_aeu299
crossref_primary_10_1007_s40620_021_01162_3
crossref_primary_10_1371_journal_pone_0204920
crossref_primary_10_1055_a_1518_5404
crossref_primary_10_1007_s00740_019_00298_0
crossref_primary_10_3390_medicina58030340
crossref_primary_10_1016_S0140_6736_24_02385_7
crossref_primary_10_1186_s13613_017_0260_y
crossref_primary_10_1016_j_jtcvs_2019_01_038
crossref_primary_10_1016_S1441_2772_23_00786_X
crossref_primary_10_1007_s00101_016_0259_z
crossref_primary_10_1016_j_mayocp_2019_12_034
crossref_primary_10_1186_s13613_016_0168_y
crossref_primary_10_1097_CCM_0000000000003701
crossref_primary_10_14814_phy2_15453
crossref_primary_10_7759_cureus_44408
crossref_primary_10_1093_ndt_gfx023
crossref_primary_10_1097_MCC_0000000000001101
crossref_primary_10_1542_pir_2021_005438
crossref_primary_10_1111_sdi_12773
crossref_primary_10_1080_10408363_2023_2242481
crossref_primary_10_1136_bmjopen_2023_074046
crossref_primary_10_1080_0886022X_2024_2404237
crossref_primary_10_3904_kjm_2019_94_4_315
crossref_primary_10_1159_000538898
crossref_primary_10_1097_MCC_0000000000000257
crossref_primary_10_3238_arztebl_2019_0833
crossref_primary_10_1159_000441283
crossref_primary_10_3389_fphys_2022_913580
crossref_primary_10_1016_j_bpa_2017_08_006
crossref_primary_10_1016_j_ekir_2017_03_015
crossref_primary_10_1097_PCC_0000000000001478
crossref_primary_10_3389_fvets_2023_1195743
crossref_primary_10_1186_s13613_024_01349_4
crossref_primary_10_1007_s00467_023_05891_4
crossref_primary_10_1007_s00467_024_06387_5
crossref_primary_10_1016_j_aan_2023_06_005
crossref_primary_10_4103_ijccm_IJCCM_295_18
crossref_primary_10_1007_s00134_024_07441_4
crossref_primary_10_1186_s40560_017_0251_y
crossref_primary_10_3389_fped_2018_00306
crossref_primary_10_1016_j_anclin_2022_10_004
crossref_primary_10_3390_jcm11154576
Cites_doi 10.1038/nrneph.2011.216
10.1001/jama.288.20.2547
10.2215/CJN.04871107
10.1152/ajplegacy.1970.219.1.114
10.1038/ki.1989.246
10.2215/CJN.07201009
10.1161/01.RES.37.5.558
10.1681/ASN.2011090907
10.1159/000102086
10.1097/MCC.0b013e32833e2fa4
10.1186/cc5713
10.1007/BF01709751
10.2215/CJN.04960511
10.1097/00003246-198108000-00008
10.1152/ajplegacy.1973.225.1.119
10.7326/0003-4819-130-6-199903160-00002
10.1152/ajplegacy.1975.229.1.93
10.1159/000102085
10.2215/CJN.00740110
10.1038/ki.1994.132
10.1124/jpet.103.059139
10.1097/00000658-197303000-00001
10.1038/ki.1979.120
10.1002/cpt1979254435
10.2215/CJN.06280612
10.1111/j.1365-2044.2009.06228.x
10.1053/j.ajkd.2008.02.371
10.1159/000166605
10.1186/1745-6215-11-50
10.1038/ki.2011.379
10.1681/ASN.2012080800
10.1016/S0140-6736(11)61454-2
10.1172/JCI113498
ContentType Journal Article
Copyright COPYRIGHT 2013 BioMed Central Ltd.
Copyright © 2013 Chawla et al. licensee BioMed Central Ltd. 2013 Chawla et al. licensee BioMed Central Ltd.
Copyright_xml – notice: COPYRIGHT 2013 BioMed Central Ltd.
– notice: Copyright © 2013 Chawla et al. licensee BioMed Central Ltd. 2013 Chawla et al. licensee BioMed Central Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1186/cc13015
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1364-8535
1466-609X
EndPage R207
ExternalDocumentID PMC4057505
oai_biomedcentral_com_cc13015
A534778252
24053972
10_1186_cc13015
Genre Multicenter Study
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: L30 DK084760
– fundername: NIDDK NIH HHS
  grantid: R01 DK080234
– fundername: NIDDK NIH HHS
  grantid: K23 DK081616
– fundername: NIDDK NIH HHS
  grantid: K23DK081616
GroupedDBID ---
0R~
29F
2WC
4.4
53G
5GY
5VS
6J9
6PF
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ACGFS
ACJQM
ADBBV
ADUKV
AEGXH
AENEX
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BFQNJ
BMC
C6C
CITATION
CS3
DIK
E3Z
EBD
EBLON
EBS
EJD
EMOBN
F5P
GROUPED_DOAJ
GX1
H13
HYE
IAO
IHR
INH
INR
ITC
KQ8
OK1
PQQKQ
RBZ
ROL
RPM
RSV
SJN
SMD
SOJ
SV3
TR2
U2A
WOQ
YOC
CGR
CUY
CVF
ECM
EIF
NPM
7X8
-5E
-5G
-BR
3V.
7X7
88E
8FI
8FJ
ABUWG
ABVAZ
ACRMQ
ADINQ
AFGXO
AFKRA
AFNRJ
BENPR
BPHCQ
BVXVI
C1A
C24
CCPQU
FYUFA
HMCUK
M1P
O5R
O5S
PIMPY
PROAC
PSQYO
UKHRP
5PM
ID FETCH-LOGICAL-b553t-503751de9fcb6ec8a1aaffc6d1f85db373bfda8f72b649190b17f0fd1e41bc683
IEDL.DBID RBZ
ISSN 1364-8535
1466-609X
IngestDate Thu Aug 21 14:11:44 EDT 2025
Wed May 22 07:13:49 EDT 2024
Fri Jul 11 01:09:19 EDT 2025
Tue Jun 17 22:05:01 EDT 2025
Tue Jun 10 21:01:21 EDT 2025
Thu Apr 03 06:49:24 EDT 2025
Tue Jul 01 03:54:27 EDT 2025
Thu Apr 24 23:01:52 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b553t-503751de9fcb6ec8a1aaffc6d1f85db373bfda8f72b649190b17f0fd1e41bc683
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://dx.doi.org/10.1186/cc13015
PMID 24053972
PQID 1545775530
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4057505
biomedcentral_primary_oai_biomedcentral_com_cc13015
proquest_miscellaneous_1545775530
gale_infotracmisc_A534778252
gale_infotracacademiconefile_A534778252
pubmed_primary_24053972
crossref_primary_10_1186_cc13015
crossref_citationtrail_10_1186_cc13015
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-09-20
PublicationDateYYYYMMDD 2013-09-20
PublicationDate_xml – month: 09
  year: 2013
  text: 2013-09-20
  day: 20
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Critical care (London, England)
PublicationTitleAlternate Crit Care
PublicationYear 2013
Publisher BioMed Central Ltd
BioMed Central
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
References JL Koyner (2976_CR28) 2010; 5
NR Loon (2976_CR19) 1989; 36
DC Brater (2976_CR15) 1979; 25
N Gibney (2976_CR4) 2008; 3
RH Bowman (2976_CR12) 1975; 229
WJ Arendshorst (2976_CR23) 1975; 37
SN Heyman (2976_CR31) 1994; 45
JE Bird (2976_CR24) 1988; 81
P Chennavasin (2976_CR25) 1979; 16
AS Levey (2976_CR22) 1999; 130
WA Knaus (2976_CR20) 1981; 9
H Hasannejad (2976_CR11) 2004; 308
SL Goldstein (2976_CR33) 2010; 5
JH Dirks (2976_CR14) 1970; 219
JV Bonventre (2976_CR8) 2007; 156
R Bellomo (2976_CR1) 2012; 380
VF Seabra (2976_CR5) 2008; 52
P Devarajan (2976_CR9) 2007; 156
RL Mehta (2976_CR29) 2002; 288
SG Coca (2976_CR2) 2012; 81
RK Hsu (2976_CR3) 2013; 24
M Burg (2976_CR13) 1973; 225
JL Alge (2976_CR17) 2013; 8
JL Vincent (2976_CR21) 1996; 22
LS Chawla (2976_CR7) 2012; 8
SM Bagshaw (2976_CR32) 2010; 11
LS Chawla (2976_CR18) 2008; 110
SM Baek (2976_CR26) 1973; 177
RL Mehta (2976_CR16) 2007; 11
K Doi (2976_CR10) 2010; 16
KM Ho (2976_CR30) 2010; 65
IE Hall (2976_CR27) 2011; 6
JL Koyner (2976_CR6) 2012; 23
7261642 - Crit Care Med. 1981 Aug;9(8):591-7
22383693 - J Am Soc Nephrol. 2012 May;23(5):905-14
23222124 - J Am Soc Nephrol. 2013 Jan;24(1):37-42
2811065 - Kidney Int. 1989 Oct;36(4):682-9
428188 - Clin Pharmacol Ther. 1979 Apr;25(4):435-9
22034509 - Clin J Am Soc Nephrol. 2011 Dec;6(12):2740-9
4714389 - Am J Physiol. 1973 Jul;225(1):119-24
4692111 - Ann Surg. 1973 Mar;177(3):253-8
8844239 - Intensive Care Med. 1996 Jul;22(7):707-10
513505 - Kidney Int. 1979 Aug;16(2):187-95
22617274 - Lancet. 2012 Aug 25;380(9843):756-66
17464129 - Contrib Nephrol. 2007;156:203-12
18953176 - Nephron Clin Pract. 2008;110(3):c145-50
10075613 - Ann Intern Med. 1999 Mar 16;130(6):461-70
23143504 - Clin J Am Soc Nephrol. 2013 Feb;8(2):184-93
2835399 - J Clin Invest. 1988 May;81(5):1630-8
20085566 - Anaesthesia. 2010 Mar;65(3):283-93
18562058 - Am J Kidney Dis. 2008 Aug;52(2):272-84
14610216 - J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9
17331245 - Crit Care. 2007;11(2):R31
25473657 - Crit Care. 2014;18(3):429
1192555 - Circ Res. 1975 Nov;37(5):558-68
22249777 - Nat Rev Nephrol. 2012 Feb;8(2):68-70
12444861 - JAMA. 2002 Nov 27;288(20):2547-53
17464130 - Contrib Nephrol. 2007;156:213-9
20736829 - Curr Opin Crit Care. 2010 Dec;16(6):545-9
5424836 - Am J Physiol. 1970 Jul;219(1):114-21
20798258 - Clin J Am Soc Nephrol. 2010 Dec;5(12):2154-65
20459801 - Trials. 2010;11:50
20299370 - Clin J Am Soc Nephrol. 2010 May;5(5):943-9
1147061 - Am J Physiol. 1975 Jul;229(1):93-8
25033085 - Crit Care. 2014;18(3):429
22113526 - Kidney Int. 2012 Mar;81(5):442-8
8007601 - Kidney Int. 1994 Apr;45(4):981-5
18322044 - Clin J Am Soc Nephrol. 2008 May;3(3):876-80
References_xml – volume: 8
  start-page: 68
  year: 2012
  ident: 2976_CR7
  publication-title: Nat Rev Nephrol
  doi: 10.1038/nrneph.2011.216
– volume: 288
  start-page: 2547
  year: 2002
  ident: 2976_CR29
  publication-title: Jama
  doi: 10.1001/jama.288.20.2547
– volume: 3
  start-page: 876
  year: 2008
  ident: 2976_CR4
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/CJN.04871107
– volume: 219
  start-page: 114
  year: 1970
  ident: 2976_CR14
  publication-title: Am J Physiol
  doi: 10.1152/ajplegacy.1970.219.1.114
– volume: 36
  start-page: 682
  year: 1989
  ident: 2976_CR19
  publication-title: Kidney Int
  doi: 10.1038/ki.1989.246
– volume: 5
  start-page: 943
  year: 2010
  ident: 2976_CR33
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/CJN.07201009
– volume: 37
  start-page: 558
  year: 1975
  ident: 2976_CR23
  publication-title: Circ Res
  doi: 10.1161/01.RES.37.5.558
– volume: 23
  start-page: 905
  year: 2012
  ident: 2976_CR6
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2011090907
– volume: 156
  start-page: 213
  year: 2007
  ident: 2976_CR8
  publication-title: Contrib Nephrol
  doi: 10.1159/000102086
– volume: 16
  start-page: 545
  year: 2010
  ident: 2976_CR10
  publication-title: Curr Opin Crit Care
  doi: 10.1097/MCC.0b013e32833e2fa4
– volume: 11
  start-page: R31
  year: 2007
  ident: 2976_CR16
  publication-title: Crit Care
  doi: 10.1186/cc5713
– volume: 22
  start-page: 707
  year: 1996
  ident: 2976_CR21
  publication-title: Intensive Care Med
  doi: 10.1007/BF01709751
– volume: 6
  start-page: 2740
  year: 2011
  ident: 2976_CR27
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/CJN.04960511
– volume: 9
  start-page: 591
  year: 1981
  ident: 2976_CR20
  publication-title: Crit Care Med
  doi: 10.1097/00003246-198108000-00008
– volume: 225
  start-page: 119
  year: 1973
  ident: 2976_CR13
  publication-title: Am J Physiol
  doi: 10.1152/ajplegacy.1973.225.1.119
– volume: 130
  start-page: 461
  year: 1999
  ident: 2976_CR22
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-130-6-199903160-00002
– volume: 229
  start-page: 93
  year: 1975
  ident: 2976_CR12
  publication-title: Am J Physiol
  doi: 10.1152/ajplegacy.1975.229.1.93
– volume: 156
  start-page: 203
  year: 2007
  ident: 2976_CR9
  publication-title: Contrib Nephrol
  doi: 10.1159/000102085
– volume: 5
  start-page: 2154
  year: 2010
  ident: 2976_CR28
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/CJN.00740110
– volume: 45
  start-page: 981
  year: 1994
  ident: 2976_CR31
  publication-title: Kidney Int
  doi: 10.1038/ki.1994.132
– volume: 308
  start-page: 1021
  year: 2004
  ident: 2976_CR11
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.103.059139
– volume: 177
  start-page: 253
  year: 1973
  ident: 2976_CR26
  publication-title: Ann Surg
  doi: 10.1097/00000658-197303000-00001
– volume: 16
  start-page: 187
  year: 1979
  ident: 2976_CR25
  publication-title: Kidney Int
  doi: 10.1038/ki.1979.120
– volume: 25
  start-page: 435
  year: 1979
  ident: 2976_CR15
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt1979254435
– volume: 8
  start-page: 184
  year: 2013
  ident: 2976_CR17
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/CJN.06280612
– volume: 65
  start-page: 283
  year: 2010
  ident: 2976_CR30
  publication-title: Anaesthesia
  doi: 10.1111/j.1365-2044.2009.06228.x
– volume: 52
  start-page: 272
  year: 2008
  ident: 2976_CR5
  publication-title: Am J Kidney Dis
  doi: 10.1053/j.ajkd.2008.02.371
– volume: 110
  start-page: c145
  year: 2008
  ident: 2976_CR18
  publication-title: Nephron Clin Pract
  doi: 10.1159/000166605
– volume: 11
  start-page: 50
  year: 2010
  ident: 2976_CR32
  publication-title: Trials
  doi: 10.1186/1745-6215-11-50
– volume: 81
  start-page: 442
  year: 2012
  ident: 2976_CR2
  publication-title: Kidney Int
  doi: 10.1038/ki.2011.379
– volume: 24
  start-page: 37
  year: 2013
  ident: 2976_CR3
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2012080800
– volume: 380
  start-page: 756
  year: 2012
  ident: 2976_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)61454-2
– volume: 81
  start-page: 1630
  year: 1988
  ident: 2976_CR24
  publication-title: J Clin Invest
  doi: 10.1172/JCI113498
– reference: 20459801 - Trials. 2010;11:50
– reference: 22249777 - Nat Rev Nephrol. 2012 Feb;8(2):68-70
– reference: 4692111 - Ann Surg. 1973 Mar;177(3):253-8
– reference: 7261642 - Crit Care Med. 1981 Aug;9(8):591-7
– reference: 14610216 - J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9
– reference: 20085566 - Anaesthesia. 2010 Mar;65(3):283-93
– reference: 23222124 - J Am Soc Nephrol. 2013 Jan;24(1):37-42
– reference: 17464129 - Contrib Nephrol. 2007;156:203-12
– reference: 20736829 - Curr Opin Crit Care. 2010 Dec;16(6):545-9
– reference: 2811065 - Kidney Int. 1989 Oct;36(4):682-9
– reference: 2835399 - J Clin Invest. 1988 May;81(5):1630-8
– reference: 8844239 - Intensive Care Med. 1996 Jul;22(7):707-10
– reference: 1147061 - Am J Physiol. 1975 Jul;229(1):93-8
– reference: 17331245 - Crit Care. 2007;11(2):R31
– reference: 22383693 - J Am Soc Nephrol. 2012 May;23(5):905-14
– reference: 20798258 - Clin J Am Soc Nephrol. 2010 Dec;5(12):2154-65
– reference: 428188 - Clin Pharmacol Ther. 1979 Apr;25(4):435-9
– reference: 513505 - Kidney Int. 1979 Aug;16(2):187-95
– reference: 23143504 - Clin J Am Soc Nephrol. 2013 Feb;8(2):184-93
– reference: 22034509 - Clin J Am Soc Nephrol. 2011 Dec;6(12):2740-9
– reference: 18562058 - Am J Kidney Dis. 2008 Aug;52(2):272-84
– reference: 25473657 - Crit Care. 2014;18(3):429
– reference: 5424836 - Am J Physiol. 1970 Jul;219(1):114-21
– reference: 8007601 - Kidney Int. 1994 Apr;45(4):981-5
– reference: 18322044 - Clin J Am Soc Nephrol. 2008 May;3(3):876-80
– reference: 1192555 - Circ Res. 1975 Nov;37(5):558-68
– reference: 25033085 - Crit Care. 2014;18(3):429
– reference: 17464130 - Contrib Nephrol. 2007;156:213-9
– reference: 18953176 - Nephron Clin Pract. 2008;110(3):c145-50
– reference: 20299370 - Clin J Am Soc Nephrol. 2010 May;5(5):943-9
– reference: 12444861 - JAMA. 2002 Nov 27;288(20):2547-53
– reference: 22113526 - Kidney Int. 2012 Mar;81(5):442-8
– reference: 22617274 - Lancet. 2012 Aug 25;380(9843):756-66
– reference: 10075613 - Ann Intern Med. 1999 Mar 16;130(6):461-70
– reference: 4714389 - Am J Physiol. 1973 Jul;225(1):119-24
SSID ssj0017863
Score 2.535681
Snippet In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. We investigated the...
Introduction In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. Methods...
In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. We investigated the...
In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages.INTRODUCTIONIn the...
INTRODUCTION: In the setting of early acute kidney injury (AKI), no test has been shown to definitively predict the progression to more severe stages. METHODS:...
SourceID pubmedcentral
biomedcentral
proquest
gale
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage R207
SubjectTerms Acute Kidney Injury - diagnosis
Acute Kidney Injury - urine
Acute renal failure
Aged
Cohort Studies
Diagnosis
Diuretics
Exercise Test - standards
Exercise Test - trends
Exercise tests
Female
Furosemide
Health aspects
Humans
Male
Middle Aged
Pilot Projects
Predictive Value of Tests
Prognosis
Prospective Studies
Retrospective Studies
Severity of Illness Index
Title Development and Standardization of a Furosemide Stress Test to Predict the Severity of Acute Kidney Injury
URI https://www.ncbi.nlm.nih.gov/pubmed/24053972
https://www.proquest.com/docview/1545775530
http://dx.doi.org/10.1186/cc13015
https://pubmed.ncbi.nlm.nih.gov/PMC4057505
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEA-lgvgifnu2lhREnxY3u_l8PMWjKhWhLRRfQj7plXZP6t5D_3tn9vbOS_XJt4VJhjCTyfxmk5kh5E3OIgiZVeVinSquEq-M165yJiipQqxNg_nOx9_k0Rn_ci7Od8jhv2_wmZbvQ4BjFtPI7zUc4jgMyD_82FwUKD00S2Ot5BV4HrHKi92eeCeT_apwQHeP4S0_VL6R3HI6s0fk4YgW6XSl3sdkJ3VPyP3j8T78KbncevNDXRfpyfhnYMyupItMHZ1hycp0PY-JngypIfQUFkH7Bf1-g6zg8wJIwAo72eGcaVj2iX6dxy7d0s_dJQj-GTmbfTr9eFSN3RMqL0TbVwK727KYTA5epqAdcy7nICPLWkTfqtbn6HRWjZfcAC7wTOU6R5Y480Hq9jnZ7RZdeklobUKGsEYrE2vuOIR4DsIoFTRzpq2dmpC2ELH9uaqUYbF2dUkBM7KjYibk7VoRNowFybEvxpUdAhMt_wykm4Frzn8NeYeatGiVwCO4MbkA1o_1rexUtFwBGBLNhOwXI8GaQkE-XO8FiyR8gtalxfKXRaypFHZZmpAXq72xWQ3AIgHADmarYtcUgigp3fxiKOY9AOZavPovEe6RB83QnsPAabdPdvubZXoNIKn3B8PPhYPBWH4DVuQVrA
linkProvider BioMedCentral
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELZQkYAL4t1AASMhOC3sZtevY0BEKW0qpKZSxcXyU00VNqjdHPrvGXudsC43biuNbVkez3i8nm8-hN57TwyhnhXKlq5omGsKobkqlDCMMmNLMQ545_kJnZ0138_JeeI5DVgYkwr8h7ynT0ME-iq67W22WG_snH42BpxwAJnfZYSwCOD68nP3jMB4pFKratoUcC6RHjU77HgL577KjqfbTnpwSuUZlIMjafoIPUyxJJ70s32M7rj2Cbo3T6_lT9HlICMIq9bi0_TfIGEv8dpjhaehoKX7tbQOn0bgCF7AJHC3xj-uwlDweQEiGCrw3IU-E7PpHD5a2tbd4MP2EtTyDJ1Nvy2-zorErVBoQuquIIH7trJOeKOpM1xVSnlvqK08J1bXrNbeKu7ZWNNGQNSgK-ZLbyvXVNpQXj9He-26dfsIl8J4uPRwJmzZqAYugAouWczwSom6VGyE6myJ5e--joYMla1zCahYJsWM0IetIqRJ5coDa8ZKxmsLp38b4l3D7cj_NPkYNCmDzcIYRiXoAcw_VL-SE1I3DEIlMh6hg6wl2JrJxO-2e0EGUUhQa916cy1DJMpY4GAaoRf93tjNBoImAmEf9GbZrskWIpe0y4tY6juG0yV5-V9L-Bbdny3mx_L48OToFXowjkQeAvziAdrrrjbuNYRTnX4TTeYPlY8j3g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQkSouiDcLpTUSglNosokfOS6lq5bSqqKtVHGx_FS3LNmqZA_8e2YS7xKXG7dIY1uWZ8Yex_PNR8i7EJhlPIhMu9xnlfBVVhupM11bwYV1eT1GvPPxCT-4qL5csssBit_GAv-Y9_RxiECfd9s2fNgfuzcu9N4u-a61sAsjyvy-YEwgh8G3T9_X7whCdlxqRcmrDA4m1sNmhx3vAN3nyfl0d5ceHFNpCuXgTJo-Ig9jMEknvfYfk3u-eUI2j-Nz-VNyPUgJorpx9Cz-OIjgS7oIVNMpVrT0P2fO07MOOULPYRK0XdDTWxwKPq9ABEMh0R32mdhl6-nRzDX-Nz1srkEvz8jFdP987yCL5AqZYaxsM4bkt4XzdbCGeyt1oXUIlrsiSOZMKUoTnJZBjA2vaggbTCFCHlzhq8JYLsvnZKNZNP4loXltA9x6pKhdXukKboAablnCykLXZa7FiJTJEqubvpCGwtLWqQR0rKJiRuT9ShHKxnrlSJsxV929RfK_Dem64Wrkf5p8QE0qdFo0IR2xBzB_LH-lJqysBMRKbDwiW0lLcDabiN-ubEGhCDPUGr9Y_lIYigqBJEwj8qK3jfVsIGpiEPdBb5FYTbIQqaSZXXW1vrt4Omev_msJd8jm6eep-np4cvSaPBh3RB417ItbZKO9Xfo3EE61ZrvzmD8M9SOp
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+and+Standardization+of+a+Furosemide+Stress+Test+to+Predict+the+Severity+of+Acute+Kidney+Injury&rft.jtitle=Critical+care+%28London%2C+England%29&rft.au=Chawla%2C+Lakhmir+S&rft.au=Davison%2C+Danielle+L&rft.au=Brasha-Mitchell%2C+Ermira&rft.au=Koyner%2C+Jay+L&rft.date=2013-09-20&rft.pub=BioMed+Central+Ltd&rft.issn=1364-8535&rft.volume=17&rft_id=info:doi/10.1186%2Fcc13015&rft.externalDocID=A534778252
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1364-8535&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1364-8535&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1364-8535&client=summon